Small cell lung cancer (SCLC) transformation is seen in approximately 3% to 14% of NSCLC cases after first line EGFR TKI treatment.[4,6] In such cases, cytotoxic drugs are commonly used according to the histologic findings. This evidence concerns the gene EGFR and small cell lung carcinoma.